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Abstract
Recombinant tissue plasminogen activator (rtPA), an enzyme that catalyzes the conversion of plasminogen to plasmin
resulting in fibrinolysis, is used for the treatment of acute ischemic strokes. The use of this medication is not without
complication. One complication of this therapy is angioedema. This complication can be life-threatening if not recognized
quickly. However, the potential for the development of angioedema after rtPA administration is not widely known. This is a
case of a 60-year-old man who suffered an acute ischemic stroke and was given rtPA. The patient subsequently developed
rapidly progressing angioedema leading to airway compromise. The patient was intubated with some difficulty and the
angioedema improved and the patient was able to be extubated the next day. Angioedema secondary to administration of
rtPA is thought to be bradykinin mediated, but the exact mechanism is unknown. Treatment with FFP, Icatibant, Ecallantide
or a C1-esterase inhibitor can be considered.
INTRODUCTION
Since 1958, thrombolysis has been used to treat acute ischemic
strokes [1]. The currently recommended fibrinolytic is recom-
binant tissue plasminogen activator (rtPA), an enzyme that cat-
alyzes the conversion of plasminogen to plasmin resulting in
fibrinolysis [2, 3]. The major complication of rtPA therapy is
intracranial hemorrhage, which occurs in 2–9% of patients [2–4].
A lesser-known, but also potentially life-threatening complica-
tion is orolingual angioedema, occurring in 1.3–5.1% of patients
[5–8]. Patients with concomitant angiotensin converting enzyme
(ACE) inhibitor use are at an increased risk of angioedema fol-
lowing rtPA [7–10], but the complication can be seen in patients
not on ACE inhibitor therapy [11–13].
Angioedema is caused by fluid moving into interstitial tis-
sues as a result of increased vascular permeability due to
inflammatory mediators. There are three major causes of
angioedema: mast cell mediated, such as allergic reactions and
non-steroidal anti-inflammatory drugs; bradykinin mediated,
such as ACE inhibitors and C1 inhibitor deficiency; and
unknown mechanisms, such as idiopathic angioedema and
fibrinolytic agents. ACE inhibitors are the leading cause of
drug-induced angioedema in the USA with 0.1–0.7% of patients
taking the drug developing angioedema [14–16].
Awareness of the possibility of angioedema development
following rtPA administration among physicians using this
drug is critically important. Although most cases require only
supportive care, we present a case of a patient with rapidly pro-
gressive angioedema requiring emergent intubation.
CASE REPORT
A 60-year old man with a history of hypertension and Crohn’s
disease was at home with his wife when he suddenly devel-
oped right sided weakness and right facial droop. The patient’s
only home medication was an ACE-inhibitor and he had no
known allergies to medications. The patient presented to the
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emergency department (ED) ~1 h after the onset of symptoms.
The patient was evaluated on arrival and given a National
Institutes of Health Stroke Scale (NIHSS) of 8 [17]. He was taken
immediately for a noncontrast head computed tomography
(CT) scan which showed several old infarcts, but no acute hem-
orrhage or hypodensities. The patient and his wife were offered
treatment with rtPA and chose to go forward with treatment.
Within 10min of initiation of rtPA therapy per National
Institute of Neurological Disorders and Stroke (NINDS) protocol,
the patient’s symptoms resolved completely [2]. Approximately
50min after rtPA was started, the patient noted significant ede-
ma of the right side of his tongue. There was no hemodynamic
instability and the patient was not having any difficulty breath-
ing. The patient was immediately evaluated by the emergency
physician and neurologist and was given intravenous diphen-
hydramine (50mg) and solumedrol (125mg). Fifteen minutes
later, the edema had progressed to involve the entire tongue
and the decision was made to intubate the patient for airway
protection. The rtPA infusion was stopped with <1mL remain-
ing to infuse. The patient was given 10mg etomidate for sed-
ation and awake fiberoptic intubation was attempted. On the
first attempt at intubation, the vocal cords were visualized and
the entire larynx was normal in appearance. However, the
patient was not successfully intubated on this attempt due to
secretions and the patient coughing/gagging. The patient’s oxy-
gen saturation was beginning to decline, so the initial attempt
was aborted. A nasal airway was placed and a jaw thrust/chin
lift maneuver was done which immediately improved the
patient’s oxygen saturation. On a second attempt at intubation,
marked edema of the entire larynx was noted and ability to dis-
cern to vocal cords was decreased, but the patient was success-
fully intubated. After successful intubation, the patient was
noted to have edema of the right submandibular area and
anterior neck down to approximately the level of the cricoid
cartilage. The edema quickly progressed to involve the left sub-
mandibular area and the left side of the neck. The patient was
admitted to the Neurology Intensive Care Unit for monitoring.
While in the ICU, the patient received scheduled doses of
diphenhydramine, famotidine and prednisone. The following
day, the edema had improved and the patient was evaluated by
respiratory therapy and found to have a cuff leak. He was suc-
cessfully extubated ~15 h after intubation and the angioedema
completely resolved after 3 days. The patient remained hospi-
talized for 6 more days and was discharged to a rehabilitation
facility. On discharge, the patient’s neurological deficits were
unchanged from initial presentation.
DISCUSSION
This case describes the development of angioedema requiring
emergent intubation subsequent to infusion of rtPA. Orolingual
angioedema develops after treatment with rtPA in 1.3–5.1% of
patients, with most cases beginning hemilingually and within
an hour of completion of rtPA infusion [6–13]. The main risk
factors for developing angioedema ofter rtPA administration
include ACE-inhibitor use (this patient was taking an ACE
inhibitor for his hypertension) (relative risk 13.6) and early
signs of infarction in the territory of the middle cerebral artery
(relative risk 6.4) [7]. Most cases of post-rtPA angioedema begin
hemilingually, usually contralateral to the area of infarct,
which may due to autonomic dysfunction resulting from
infarction of the insular cortex [7, 8]. While most cases of rtPA
associated angioedema are mild and self-limiting, there is a
risk of rapidly progressing edema that could potentially lead to
asphyxia.
Angioedema following rtPA infusion is thought to be brady-
kinin mediated [18]. RtPA generates plasmin, which cleaves
kininogen into bradykinin. Bradykinin is a vasodilator and
increases vascular permeability, allowing fluid to move into
interstitial tissues. Bradykinin-mediated angioedema is also
seen with ACE inhibitors and C1-esterase deficiency [19]. As
such, patients who are taking ACE inhibitors are more suscep-
tible to rtPA-induced angioedema due to higher levels of circu-
lating bradykinin.
When angioedema is caused by bradykinin, treatment with
antihistamines, corticosteroids and epinephrine is generally
ineffective and is not recommended [20]. However, initial and
maintenance doses of these medications are often adminis-
tered. Many cases will resolve with only supportive care. Fresh
frozen plasma (FFP), Icatibant (a bradykinin B2 receptor antag-
onist) and Ecallantide (a recombinant protein that inhibits
Kallikrein) have been used in ACE-inhibitor induced angioede-
ma and may be helpful in rtPA associated angioedema given
that both processes are bradykinin mediated [21–23]. Because
administration of rtPA activates the complement cascade, C1-
esterase inhibitor may improve angioedema associated with
rtPA administration and allow avoidance of airway maneuvers
[24]. Although often unnecessary, intubation should be con-
sidered as soon as angioedema develops as symptoms can pro-
gress rapidly. Patients with symptoms limited to the lips and
anterior tongue generally do not require intubation, but angioe-
dema progressing to the floor of the mouth, palate, hypophar-
ynx or larynx increases the likelihood that patient will require
intubation. Awake fiberoptic intubation either nasally or orally
is likely the best choice for intubation. Direct laryngoscopy is
likely to be difficult due to edema and carries the risk of bleed-
ing secondary to trauma. Supraglottic devices may be temporiz-
ing in the event that a definitive airway cannot be secured. A
surgical airway is likely to be exceptionally difficult due to
excessive bleeding in a patient that just received rtPA.
Although a fairly uncommon occurrence, angioedema is a
potentially life-threatening complication of rtPA administra-
tion. Physicians who administer rtPA must be aware of this
risk, particularly in patients who are also taking an ACE inhibi-
tor. Treatment with FFP, Icatibant, Ecallantide or a C1-esterase
inhibitor can be considered and a potential intubation
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